Back in December of 2014 the U.S. Food and Drug Administration approved Blincyto (blinatumomab) to treat patients with acute lymphoblastic leukemia, or B-cell ALL. This rare form of acute lymphoblastic leukemia occurs in bone marrow and the formation of many immature white blood cells, known as B-cell lymphoblasts.
Blincyto is a treatment for B-cell ALL intended to be used in patients whose cancer has relapsed or in patients who did not respond to previous treatments. Blincyto works by using parts of the body's immune system to fight against B-cell ALL.
The Canadian Product Monograph has been updated recently in order to give patients and doctors notice of a dangerous condition linked to Blincyto usage, Pancreatitis. Pancreatitis is a disease that comes from inflammation in the pancreas and it can result in abdominal pain, nausea, vomiting and in some extreme cases, death.